These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 32057100)
1. Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium. Mondelaers V; Ferster A; Uyttebroeck A; Brichard B; van der Werff Ten Bosch J; Norga K; Francotte N; Piette C; Vandemeulebroecke K; Verbeke C; Schmidt S; Benoit Y; Lammens T; De Moerloose B Br J Haematol; 2020 Jul; 190(1):105-114. PubMed ID: 32057100 [TBL] [Abstract][Full Text] [Related]
2. Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia. Vieira Pinheiro JP; Müller HJ; Schwabe D; Gunkel M; Casimiro da Palma J; Henze G; von Schütz V; Winkelhorst M; Würthwein G; Boos J Br J Haematol; 2001 Apr; 113(1):115-9. PubMed ID: 11328290 [TBL] [Abstract][Full Text] [Related]
3. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Albertsen BK; Schrøder H; Ingerslev J; Jakobsen P; Avramis VI; Müller HJ; Carlsen NT; Schmiegelow K Br J Haematol; 2001 Dec; 115(4):983-90. PubMed ID: 11843837 [TBL] [Abstract][Full Text] [Related]
4. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report. Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766 [TBL] [Abstract][Full Text] [Related]
5. Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Vieira Pinheiro JP; Lanversa C; Würthwein G; Beier R; Casimiro da Palma J; von Stackelberg A; Boos J Leuk Lymphoma; 2002 Oct; 43(10):1911-20. PubMed ID: 12481884 [TBL] [Abstract][Full Text] [Related]
6. [The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia]. Takahashi H; Koh K; Kato M; Isobe K; Yasui N; Mori M; Akiyama K; Kikuchi A; Hanada R Rinsho Ketsueki; 2013 Apr; 54(4):370-7. PubMed ID: 23666219 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007. Schrey D; Borghorst S; Lanvers-Kaminsky C; Hempel G; Gerss J; Möricke A; Schrappe M; Boos J Pediatr Blood Cancer; 2010 Jul; 54(7):952-8. PubMed ID: 20108339 [TBL] [Abstract][Full Text] [Related]
8. A comparison of hypersensitivity reactions between intravenous and intramuscular applications of native Odaman Al I; Özdemir N; Zengin Ersoy G; Bayram C; Vupa Çilengiroğlu Ö; Arslantaş E; Paslı Uysalol E; Ayçiçek A J Oncol Pharm Pract; 2023 Sep; 29(6):1454-1460. PubMed ID: 36942380 [TBL] [Abstract][Full Text] [Related]
10. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Tong WH; Pieters R; Kaspers GJ; te Loo DM; Bierings MB; van den Bos C; Kollen WJ; Hop WC; Lanvers-Kaminsky C; Relling MV; Tissing WJ; van der Sluis IM Blood; 2014 Mar; 123(13):2026-33. PubMed ID: 24449211 [TBL] [Abstract][Full Text] [Related]
11. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524 [TBL] [Abstract][Full Text] [Related]
12. Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. Gupta S; Wang C; Raetz EA; Schore R; Salzer WL; Larsen EC; Maloney KW; Mattano LA; Carroll WL; Winick NJ; Hunger SP; Loh ML; Devidas M J Clin Oncol; 2020 Jun; 38(17):1897-1905. PubMed ID: 32275469 [TBL] [Abstract][Full Text] [Related]
13. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia. Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829 [TBL] [Abstract][Full Text] [Related]
14. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia. Vrooman LM; Kirov II; Dreyer ZE; Kelly M; Hijiya N; Brown P; Drachtman RA; Messinger YH; Ritchey AK; Hale GA; Maloney K; Lu Y; Plourde PV; Silverman LB Pediatr Blood Cancer; 2016 Feb; 63(2):228-33. PubMed ID: 26376459 [TBL] [Abstract][Full Text] [Related]
15. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia. Dibenedetto SP; Di Cataldo A; Ragusa R; Meli C; Lo Nigro L J Clin Oncol; 1995 Feb; 13(2):339-44. PubMed ID: 7844595 [TBL] [Abstract][Full Text] [Related]
16. Activity and toxicity of intramuscular 1000 iu/m Sidhu J; Masurekar AN; Gogoi MP; Fong C; Ioannou T; Lodhi T; Parker C; Liu J; Kirkwood AA; Moorman AV; Das K; Goulden NJ; Vora A; Saha V; Krishnan S Br J Haematol; 2022 Jul; 198(1):142-150. PubMed ID: 35348200 [TBL] [Abstract][Full Text] [Related]
17. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study. Würthwein G; Lanvers-Kaminsky C; Gerss J; Möricke A; Zimmermann M; Stary J; Smisek P; Attarbaschi A; Nath C; Zucchetti M; Rizzari C; Schrappe M; Boos J; Ther Drug Monit; 2020 Jun; 42(3):435-444. PubMed ID: 32022785 [TBL] [Abstract][Full Text] [Related]
19. Asparaginase activities during intensified treatment with pegylated Lanvers-Kaminsky C; Niemann A; Eveslage M; Beck J; Köhnke T; Martin S; de Wit M; Spriewald B; Hauspurg H; Hoelzer D; Boos J; Gökbuget N Leuk Lymphoma; 2020 Jan; 61(1):138-145. PubMed ID: 31480965 [TBL] [Abstract][Full Text] [Related]
20. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia. Wenner KA; Vieira Pinheiro JP; Escherich G; Wessalowski R; Jorch N; Wolff J; Stehn M; Kohlschütter A; Boos J; Janka-Schaub GE Klin Padiatr; 2005; 217(6):321-6. PubMed ID: 16307417 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]